Pap Smear News and Research

RSS

The Pap test, also called a Pap smear, checks for changes in the cells of your cervix. The cervix is the lower part of the uterus (womb) that opens into the vagina (birth canal). The Pap test can tell if you have an infection, abnormal (unhealthy) cervical cells, or cervical cancer.

Obama's deficit plan earns raves, pans from editorial boards; more views on abortion and planned parenthood

I've proposed a balanced approach that looks at the entire budget for savings. The third step is to reduce the growth in health care spending in order to strengthen Medicare and Medicaid for future generations. We will get rid of wasteful subsidies and fraud that cost Medicare billions of dollars each year. We'll cut spending on prescription drugs by helping to get generic brands of medicine to market faster.

15 Apr 2011

mtm’s p16 and Ki-67 dual staining test identifies high-grade cervical disease in women with ASC-US and LSIL

mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the publication of a new paper showing that dual staining for p16 and Ki-67 can pinpoint the underlying high-grade cervical disease with a high degree of sensitivity and specificity in women with ASC-US or LSIL cytology results.

31 Mar 2011

Scientist argues cost-effectiveness analysis should play bigger role in American health care system

Cost-effectiveness analysis should play a bigger role in the American health care system, argued a University of Chicago researcher Friday at the annual conference of the American Association for the Advancement of Science.

19 Feb 2011

Initiative to eliminate cervical cancer in North Carolina

Patricia Gregory of Cary was only 24 years old when she was diagnosed with cervical cancer. Now a mother of an 11-year-old daughter, she considers herself blessed to have a child, as cervical cancer can make women unable to bear children.

21 Jan 2011

VEREGEN Ointment added as new therapeutic option in 2010 CDC STD Treatment Guidelines

PharmaDerm, a division of Nycomed US Inc., announced today that VEREGEN (sinecatechins) Ointment, 15%, a topical medication for the treatment of external genital and perianal warts, has been added as a new therapeutic option in the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.

6 Jan 2011

Genetic screening for Lynch syndrome as cost-effective as other cancer screening procedures

Myriad Genetics, Inc. today said results from a major health economics study in Cancer Prevention Research, a journal of the American Association for Cancer Research (AACR), found that screening for inherited gene mutations in the genes that cause a major colorectal cancer syndrome called Lynch Syndrome, is both medically and cost effective.

30 Nov 2010

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

Annual conventional Pap smear is cost effective to reduce cancer incidence and mortality

A study of the options for reducing cancer incidence and mortality among women who have been treated for precancerous cervical lesions found that an annual conventional Pap smear is a cost effective strategy.

21 Oct 2010

Scientists identify mechanism that regulate nuclear size

Size matters when it comes to the nucleus of a cell, and now scientists have discovered the signals that control how big the nucleus gets. Nuclear size varies not only among different species, but also in different types of cells in the same species and at different times during development. In addition, cancer cells are known to develop larger nuclei as they become more malignant. Screening for cervical cancer, for example, involves looking for grossly distorted nuclei in cervical cells collected during a Pap smear.

15 Oct 2010

Cancer patients getting unnecessary tests: Study

US researchers revealed that many cancer patients with only a few years to live often continue to get routine mammograms or blood tests for prostate cancer even though they are not likely to live long enough to benefit from them. This not only wastes money but also exposes patients to unnecessary worry and distress.

12 Oct 2010

Optical technology shows potential for prescreening patients at high risk for lung cancer

Researchers from Northwestern University and NorthShore University HealthSystem (NorthShore) have developed a method to detect early signs of lung cancer by examining cheek cells in humans using pioneering biophotonics technology.

6 Oct 2010

Bayer’s new oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved a new oral contraceptive, Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).

28 Sep 2010

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Bio-Reference Laboratories, Inc. (Except for Per Share Data or where otherwise noted, numbers are in thousands) announced that the Company recorded current quarter revenues of $121,719, the best ever quarter in terms of revenues in corporate history and an increase of 25% over the $97,424 recorded in the third quarter, fiscal year 2009.

26 Aug 2010

Fewer young women going for regular pap smears

According to new research findings, the number of young women going for a regular Pap smear test is dwindling. This test is a simple procedure that looks at the cervical cells and can detect cervical cancer early on. In 2001-02, 67% Australian women aged 20-69 went for a Pap smear, a number that went down to 60% in 2008-09. These are the lowest rates in the decade.

24 Aug 2010

Patient navigator program to educate Hmong women on cervical cancer

The Asian-American community of Hmong women in California carries a stunning burden of cervical cancer and resulting mortality four times as high as non-Hispanic white women in California do.

7 Aug 2010

Norwegian cervical screening program begins reimbursing for liquid-based cytology

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that on July 1, 2010, the Norwegian cervical screening program began reimbursing for liquid-based cytology (LBC).

6 Aug 2010

Zetiq reports self declaration CE mark of conformity for cervical cancer diagnostic kit

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports that it has fulfilled the essential requirements towards issuing a self declaration CE mark of conformity for its diagnostic product for identification of cervical cancer in cytological specimens.

27 Jul 2010

Screening for HPV genotypes 16 and 18 helps detect cervical pre-cancer missed by Pap test

Roche today announced that data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) U.S. registration trial of over 47,000 women demonstrate that two human papillomavirus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test.

From Roche Sequencing and Life Science 9 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports the successful completion of another clinical trial to validate the effectiveness of the company's technology for early identification and diagnosis of cervical cancer, in conventional cytological smears.

24 Jun 2010